Amarin sources the active pharmaceutical ingredient (API) for Vascepa (icosapent ethyl) primarily from supply partners in Europe and Asia, particularly Japan and China in the past. However, in recent years, it has diversified and secured long-term contracts with multiple suppliers to ensure redundancy and minimize risk.
🇮🇪 Manufacturing in Ireland
Amarin's finished-dose manufacturing facility is located in Ireland (at its supplier Patheon, a Thermo Fisher Scientific company). That’s where the final encapsulation and packaging of Vascepa take place before it's shipped to the U.S. and other global markets.
So your logic is generally correct:
API imports into Ireland are NOT subject to U.S. tariffs.
Tariffs under the new Trump pharmaceutical policy would only affect products imported into the U.S., not API imports into Ireland or within the EU.
Since Ireland is not targeted by the tariffs, Amarin's branded Vascepa avoids those tariffs when reimported into the U.S.
Strategic Implication
This setup gives Amarin a competitive edge over generics like Hikma or Dr. Reddy's, whose finished drugs (or API and fill-finish both) may come directly from tariff-targeted countries like India or China. This may increase costs for generics trying to undercut Vascepa’s price.
In summary:
API sourcing: Global (including China/Japan), but used in Ireland.
Final manufacturing: Ireland.
Tariff impact: Negligible for Amarin due to EU-based production; potential cost pressure on generic competitors importing from Asia directly into the U.S.
Market Data 
Markets 
